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ABSTRACT
Human ovarian cancer is diagnosed in the late, metastatic stages but the 
underlying mechanisms remain poorly understood. We report a surprising functional 
link between CD151-α3β1 integrin complexes and the malignancy of serous-type 
ovarian cancer. Analyses of clinical specimens indicate that CD151 expression is 
significantly reduced or diminished in 90% of metastatic lesions, while it remains 
detectable in 58% of primary tumors. These observations suggest a putative tumor-
suppressing role of CD151 in ovarian cancer. Indeed, our analyses show that knocking 
down CD151 or α3 integrin enhances tumor cell proliferation, growth and ascites 
production in nude mice. These changes are accompanied by impaired cell-cell contacts 
and aberrant expression of E-cadherin, Mucin 5AC and fibronectin, largely reminiscent 
of an epithelial to mesenchymal transition (EMT)-like change. Importantly, Slug, a 
master regulator of EMT, is markedly elevated. Knocking down Slug partially restores 
CD151-α3β1 integrin complex-dependent suppression of cell proliferation. Moreover, 
disruption of these adhesion protein complexes is accompanied by a concomitant 
activation of canonical Wnt signaling, including elevated levels of β-catenin and 
Axin-2 as well as resistance to the inhibition in β-catenin-dependent transcriptional 
complexes. Together, our study demonstrates that CD151-α3β1 integrin complexes 
regulate ovarian tumor growth by repressing Slug-mediated EMT and Wnt signaling. 
INTRODUCTION
Ovarian cancer is the leading cause of death among 
gynecologic cancers and the fifth most common cause of 
cancer related death in the United States. Nearly 70% of 
newly diagnosed ovarian tumors are in the late, metastatic 
stages of disease [1]. Clinically, treatment for serous 
(the most common cell type) ovarian cancer is surgical 
resection followed by combination platinum- and taxol-
based chemotherapies. Unfortunately, 20% of patients 
are resistant to this regimen and most patients that are 
initially responsive will become resistant and ultimately 
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succumb to their disease [2, 3]. Despite the aggressive 
yet predictable route of tumor dissemination and high 
failure rate of current therapies, the molecular and cellular 
mechanisms underlying this cancer type remain poorly 
defined [4, 5]. Hence, a better mechanistic understanding 
of ovarian cancer progression and metastasis is urgently 
needed in order to develop more effective target-based 
therapies.
As a family of heterodimeric adhesion receptors, 
integrins are widely recognized for their role in controlling 
tumor cell interactions with the extracellular matrix 
(ECM) and neighboring cells in human epithelia-origin 
ovarian cancer [1, 6]. Notably, elevated expression 
of RGD-based integrins, including αvβ3 and α5β1, 
along with their ligands vitronectin and fibronectin, are 
strongly associated with accelerated ovarian tumor cell 
proliferation and progression [7, 8]. Such functional 
links appear to be related to a concomitant disruption in 
E-cadherin-mediated cell-cell contacts and the induction 
of epithelial to mesenchymal transition (EMT) [9, 10]. For 
instance, in SK-OV-3ip cells, the expression of fibronectin 
and its receptor α5β1 integrin are markedly elevated 
upon removal of E-cadherin [7]. Thus, there is strong 
evidence that integrins contribute to the development and 
progression of human ovarian cancer by impacting cell-
ECM and E-cadherin-dependent cell-cell interactions.
In contrast to RGD-based integrins, the role of 
laminin-binding (LB) integrins, including α3β1, α6β1 
and α6β4, is less defined, particularly with regards to the 
progression of human ovarian cancer. In some studies 
α6β4 integrin is suggested to be a promoter of ovarian 
cancer cell invasiveness [11]. In contrast, α3β1 integrin 
appears to contribute to the maintenance of stable cell-
cell contact by regulating the activity of small GTPase 
Rho A, thereby conferring a potential tumor-suppressive 
function [12, 13]. In fact, several studies have reported 
that expression of α3 integrin is inversely correlated 
with the metastatic potential of human ovarian cancer, 
particularly regarding peritoneal dissemination [14, 15]. 
Thus, LB integrins are likely a central player in controlling 
the malignancy of ovarian cancer. 
Recently, CD151, a master regulator of LB integrin 
function and signaling, has also been implicated in 
the progression of ovarian cancer. As a member of the 
tetraspanin family with four transmembrane domains, 
CD151 plays a variety of roles in multiple stages of 
human cancer development and progression [12, 16, 17]. 
For instance, CD151 has been suggested to promote tumor 
cell invasiveness and drug sensitivity through regulation 
of α6 integrins (α6β1 and α6β4) [18, 19]. A similar role 
has been recently implicated for CD151 in the progression 
of ovarian cancer [20]. However, there is also evidence 
that attenuation of CD151 expression impairs α3β1 
integrin-dependent cell adhesion and motility over laminin 
substrates in a number of human carcinoma types. These 
effects are frequently accompanied by a concomitant 
disruption in E-cadherin-mediated cell–cell contacts 
[12, 17], implying a putative tumor-suppressive role for 
CD151-α3β1 integrin complexes. Clinically, the direct 
sloughing to the peritoneal cavity is considered a primary 
disseminating route for ovarian cancer, as opposed to 
vascular or lymphatic trafficking in other carcinoma 
types, such as breast or prostate cancer [1]. In this regard, 
adhesion complexes, such as CD151-α3β1 integrin, may 
have a strong impact on ovarian cancer progression and 
metastasis through controlling cell-cell contact. Thus, 
available observations on the function of CD151 and 
its associated LB integrins in human ovarian cancer are 
conflicting and need clarification.
Here we report a functional role of CD151 and its 
associated α3β1 integrin in human serous-type ovarian 
cancer. Human tumor tissue arrays (TMA) were adopted 
for evaluation of the clinical relationship between CD151 
and ovarian tumor malignancy. Xenograft and signaling 
analyses were then conducted to delineate the functional 
cascade of CD151-α3β1 integrin complexes during ovarian 
tumor growth and progression. Our results indicate that 
CD151-α3β1 integrin complexes suppress ovarian cancer 
malignancy largely by counteracting EMT-like processes 
as well as inhibiting Slug activation and canonical Wnt 
signaling. Hence, our study for the first time illustrates that 
CD151-α3β1 integrin complexes and associated pathways 
regulate ovarian tumor growth and progression and may 
serve as potential therapeutic targets against this lethal 
human cancer.
RESULTS
CD151 expression is inversely associated with the 
malignancy of human serous-type ovarian cancer 
To evaluate the clinical significance of CD151 
expression in human ovarian cancer, IHC analyses were 
conducted on a tumor tissue array (TMA) harboring 
normal ovarian tissue, as well as papillary serous 
adenocarcinomas varying in grade and metastatic status 
(Fig. 1A). By staining with a CD151-specific monoclonal 
antibody (Fig. 1B), we found that CD151 was only 
weakly expressed in the epithelium of the normal human 
ovary (Fig. 1C). In contrast, significant CD151 staining 
was detected on the plasma membrane of tumor cells, 
and displayed a wide range of intensities between tumor 
tissue samples (Fig. 1C). Notably, a moderate or strong 
degree of expression of CD151 was detected in 58% 
of primary ovarian tumors, but in < 10% of metastatic 
tumors (p < 0.0055) (Fig. 1D). A similar trend was found 
in another independent TMA for which matched primary 
and metastatic tumor samples from 7 individual patients 
were evaluated (Fig. 1E) ( p < 0.024). It is also worth 
noting that the fallopian tube, another site for serous –
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type ovarian cancer origin [21], displayed a basal-lateral 
staining pattern for CD151 (Fig. 1F). Moreover, consistent 
with decreased CD151 protein in metastatic tumors was 
evidence of the heterozygous loss and a marked reduction 
in mRNA for this gene in the majority of TCGA ovarian 
tumor samples (Fig. 1G) [22]. There was, however, 
minimal association between CD151 expression and 
ovarian tumor grade or stage, which contrasts to prior 
reports on the expression of this protein in other cancer 
types [19, 23, 24]. Together, these observations indicate a 
significant inverse association between CD151 expression 
and metastatic status, suggesting a potential suppressive 
role of CD151 during ovarian tumor progression.
CD151 suppresses ovarian cancer cell 
proliferation, tumor growth, and ascites 
production
Next, we investigated the functional role of CD151 
using cultured human serous-type ovarian tumor cell lines. 
Initially, our FACS analyses indicated that the degree 
of surface expression of CD151 and its associated LB 
integrins (α3, α6 and β4) were highly variable between 
ovarian cancer cell lines, similar to their RGD-based 
counterparts (e.g., α2β1 or α5β1 integrin) (Figure 2A). 
Interestingly, most of these lines, except OVCAR-8, 
displayed typical epithelia-like morphologies as reflected 
Figure 1: CD151 expression in human serous-type ovarian tumors. A Clinical parameters of TMA harboring primary tumors 
and metastatic lesions across age groups and grades. B Validation of IHC staining of CD151 in human ovarian tumors . Left panel: Non-
immune IgG control; Right panel: CD151antibody. C Representative images of CD151 staining of varying intensity. a, normal ovary. 
b-d: ovarian tumors. e: metastatic lesion. Scale bar: 100 µm. D Distribution of CD151 staining in primary tumors and metastatic lesions 
(Biomax, n = 82). Based on the antibody staining of tissue sections, tumor samples were divided into the negative/weak or moderate/strong 
group. The numbers of tumor samples per group were indicated. E Analyses of CD151 expression with in-house TMA housing 7 pairs of 
matched human primary and metastatic ovarian tumors. Patient characteristics described in prior studies [64]. F CD151staining in fallopian 
tube. G Plot of gene copy number vs mRNA expression of CD151 in the TCGA ovarian cancer samples was generated as previously 
described [22]. Homdel: Homozygous deletion; Hetloss: Heterozygous loss; Gain: Copy number increase; Amp: Amplification.
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Figure 2: CD151 expression and its role in ovarian tumor cell proliferation. A The surface expression of CD151 and its 
molecular partners in cultured human ovarian cancer cell lines. The mean fluoresce intensity (M.F.I) represents an average of fluorescence 
intensity measurement from a total of 10,000 cells on flow cytometry. Semi-confluent human ovarian cancer cell lines, including OVCAR-5, 
OVCAR-8, OVCAR-420, OVCAR-429, OVCAR-433 and CAROV3 were detached by non-enzymatic buffer and incubated with anti-
CD151 (5C11), α3 (X8), α6 (GoH3), β4 (3E1), α2 (IIE10) and α5 (BIIG2). B Changes in cell proliferation over indicated periods of time 
were determined using the MTT assay. Cell proliferation index was calculated on the basis of OD reading. *: p < 0.05; **: p <0.01. C 
CD151 knockdown in human ovarian cancer cell lines, OVCAR-5 and OVCAR-420. Monoclonal antibody 1A5 was used for CD151 
blotting. β-actin was blotted as loading control. 
Figure 3: CD151 ablation enhances ovarian tumor growth and ascites production. A Ectopic analyses of ovarian tumor 
growth. The back flanks of nude mice were subcutaneously injected with control and CD151-ablated OVCAR-5 cells respectively and 
subsequently measured for tumor appearance and growth over the indicated periods of (n =10). B Kaplan-Meier survival curve. Equal 
numbers of immuno-deficient mice were given an intra-peritoneal injection of OVCAR-5 cells with or without CD151 ablation (n = 10). 
C H & E stained sections of ovarian tumors derived from subcutaneously injected OVCAR-5 cells. a, c: control b, d: CD151 knockdown. 
Scale bar: 50 µm. 
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by a high expression of cell surface E-cadherin.
Because OVCAR-5 and OVCAR-420 displayed 
significantly higher expression of CD151 and LB integrins 
(Figure 2A), these lines were selected as our representative 
models for subsequent functional analyses. As shown in 
Fig. 2A, upon CD151 ablation by stable expression of a 
well-defined shRNA from prior studies [18, 19, 25, 26], 
the proliferation of OVCAR-5 and OVCAR-420 cells 
increased by 60% and 53%, respectively. However, there 
were minimal changes in cell motility or apoptosis of 
tumor cells upon CD151 removal (data not shown). Given 
the strong influence of CD151 ablation on cell proliferation 
(Fig. 2B), we next evaluated the role of CD151 in ovarian 
tumor growth and metastasis by applying ex vivo xenograft 
models in immunocompromised mice. As shown in Fig. 
3A, tumors derived from subcutaneously injected CD151-
deficient OVCAR-5 cells grew significantly faster in mice, 
compared to the control group (p < 0.05). Furthermore, 
there was enhanced ascites production and a concomitant 
decrease in tumor-free survival in mice injected with 
CD151-deficient tumor cells (4.3 vs 7.5 weeks, p < 0.005) 
(Fig. 3B). Moreover, the tumors derived from CD151-
ablated OVCAR-5 cells displayed typical high-grade 
serous tumor histomorphologic features. Notably, these 
ovarian tumors had apparent nuclear pleiomorphism, 
prominent nucleoli, a high mitotic index, and extensive 
necrosis (up to 50% of tumor volume). Collectively, data 
from our in vitro and xenograft analyses consistently 
Figure 4: Impact of CD151 ablation on ovarian tumor cell-cell contact. A Typical morphologies and antibody staining of 
OVCAR-5 cells with or without CD151 knockdown (control or KD). a-b: Image of cells cultured for 17-24 hours; c-d staining of cell surface 
CD151; e-f staining of cell surface E-cadherin. c-f, cells were stained alive on ice with antibodies prior to being fixed. a, c, e: Control; b, 
d, f: CD151 knockdown (KD). Red- antibody staining; Green: GFP. B Change in expression of surface molecules in OVCAR-5 cells upon 
CD151 ablation. M.F.I ( Mean fluorescence intensity) was determined by FACS analyses. C Radiography of [3H]-labeled tetraspanin- and 
integrin-associated protein complexes. Reciprocal co-immunoprecipitation (Co-IP) of CD151 and LB integrins was conducted for ovarian 
cancer cell lines IgRov, SKOV3 and OVCAR-5. Tumor cells expressing control (CT) or CD151 shRNA (KD) were included. Antibodies 
used for Co-IP were IIE10, X8, GÖH3 and 5C11 for integrin α2, α3, α6 and CD151, respectively. D Analysis of the physical interaction 
between LB integrins and claudin-3. Multiple ovarian tumor cell lines (SKOV3, OVC-5 and OVCAR-8) were labeled with biotin, followed 
by lysing in 1.0% Brij96 buffer as previously described [65] . After Co-IP with either α3 or α6 antibodies (X8 or GÖH3), the immune 
complexes were blotted with claudin-3-specific antibody or Avidin-conjugated HRP.
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suggest a strong suppressive role of CD151 in ovarian 
tumor growth and progression. 
Impact of CD151 removal on cell-cell contact and 
α3β1 integrin-associated protein complexes
There is increasing evidence that the accelerated 
growth and progression of human ovarian carcinoma is 
associated with diminished or reduced cell-cell contact [1, 
21]. CD151 and its associated α3β1 integrin are pivotal 
players in stabilizing cell-cell contacts in normal and 
malignant epithelial cells [12, 17]. We therefore tested 
the notion that CD151 and α3β1 integrin act together 
to suppress ovarian tumor growth and progression by 
influencing tumor cell-cell contacts within the tetraspanin-
enriched membrane microdomain (TEMM). As shown 
in Fig. 4A, CD151 removal in OVCAR-5 cells led to 
a switch from the epithelia-like sheet to a scattered 
fibroblast-like appearance, accompanied by a marked 
reduction in surface expression of E-cadherin, compared 
to the control cells. Similar changes were also detected 
in several other ovarian tumor cell lines, including 
OVCAR-420 and CAROV3 (data not shown). In line 
with these observations is a marked decrease in the surface 
expression of E-cadherin when CD151 was knocked 
down by 90%, according to our FACS analyses (Fig. 4B). 
On average, the surface level of E-cadherin in CD151-
knockdown cells decreased by 33.5% ± 1.0% (n = 3, p 
< 0.001). These results are consistent with prior reports 
on the effect of CD151 ablation in other types of human 
carcinoma cells [12, 17]. Because E-cadherin-associated 
cell-cell contacts confer an inhibitory role in ovarian 
tumor cell growth and dissemination [27], our data imply 
that CD151 may suppress ovarian cancer malignancy by 
stabilizing cell-cell contacts between carcinoma cells.
Since tetraspanin molecules like CD151 are known 
to function within TEMM [28, 29], we next evaluated 
the impact of disrupting CD151 on the integrity of LB 
integrin-enriched protein complexes in ovarian cancer 
cells. Our co-immunoprecipitation analyses with [3H]-
Figure 5: CD151-associated α3 integrin suppresses 
ovarian tumor cell proliferation. A Cell proliferation 
Index (mean + SEM, n =5). Cells seeded into 24 well plates 
were treated with indicated siRNA and 48 hrs later analyzed by 
MTT assay. B Immunoblotting of α3 integrin and E-cadherin 
protein in OVCAR-5 cells after being treated siRNA for 72 hrs. 
The fold change in protein level was calculated on the bases of 
densitometry analyses. C Plot of gene copy number vs mRNA 
expression of α3 integrin in TCGA ovarian cancer samples was 
generated as previously described [22]. Hetloss: Heterozygous 
loss; Gain: Increase in copy number; Amp: Amplification.
Figure 6: A functional link between CD151, EMT and 
Slug in ovarian cancer cells. A Effect of CD151 ablation 
on Slug expression in OVCAR-5 and OVCAR-420 cells. Cells 
were lysed in RIPA buffer and blotted with indicated antibodies. 
B Induction of Fibronectin and Mucin5AC in CD151-deficient 
tumor cells. OVCAR-5 and OVCAR-420 cells with or without 
CD151 knockdown (KD) were lysed in RIPA buffer and blotted 
with indicate antibodies. C Effect of Slug knockdown on the 
proliferation of CD151-deficient OVCAR-5 cells (left panel). 
Blotting of Slug protein in control and knockdown cells (right 
panel). Bottom panel, proliferation index of control and Slug-
knockdown cells was assessed by the MTT assay. For A-C, 
the fold change in protein level was estimated according to 
densitometry analyses.
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Table 1: List of differentially expressed genes in OVCAR-5 ovarian cancer cells upon CD151 
removal. Fold changes were obtained by calculating the ratio of the mean of expression intensity 







MUC5AC AW192795 proliferation 34.99 0.002573
KIAA1199 AB033025 cellular proliferation 17.57 0.031699
RNF43 NM_017763 promotes cell growth 6.92 0.018189
S100A2 NM_005978 cell cycle progression and differentiation 5.25 0.028039
LGR4 NM_018490 Epithelial cell proliferation 3.79 0.006977
ID-1 D13889 tumour growth and angiogenesis 3.54 0.108128
LIF NM_002309 cell growth by inhibiting differentiation 2.83 0.017261
KYNU D55639 catabolism of Trp metabolism 5.4 0.030945
SLC39A4 NM_017767 zinc metabolism 5.23 0.010953
CD55 CA448665 protein metabolism 3.78 0.030651
AKR1B10 NM_020299 metabolism 3.38 0.049357
ALDH3B1 BC002553 aldehydes metabolism 3.34 0.018712
GCNT3 NM_004751 mucin-type biosynthesis 3.34 0.04714
SLC16A3 AL513917 Lactic acid and pyruvate transport 3.33 0.072933
CAMK2N1 NM_018584 Ca++ metabolism 2.93 0.022496
SAT1 M55580 Spermidine metabolism 2.83 0.024851
Sox4 AL136179 Cell fate 4.9 0.024132
FOXP1 AW080845 cell fate 4.24 0.01093
FN1 BC005858 cell motility 4.03 0.039951
JAG1 U73936 cell fate 2.69 0.036003
SLC1A1 AW235061 transporting glutamate 4.13 0.030336
RGS2 NM_002923 Inhibits signal transduction 3.42 0.017092
ANP32A NM_006305  transcriptional regulation -2 0.472994
ANKRD12 X80821  transcriptional regulation -2.19 0.027674
SNF1 NM_014840 Survival, invasion and metastasis -2.34 0.038872
SGEF AI989530 protein binding -2.45 0.013114
Claudin-11 AW264204 Tight junciton -2.8 0.034391
BMP2K AI735391 differentiation. -3.28 0.02009
COTL1 AJ227860  regulate the actin cytoskeleton. -3.37 0.007368
RBMS1 AA428240 protein binding -3.39 0.062653
ST6GALNAC1 NM_030965 glycosylaiton -4.98 0.027494
NMRAL1 AI080701 Redox sensor protein. -5.19 0.011539
CD151 NM_004357 cell adhesion -7.21 0.179191
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palmitate-labeled tumor cells indicate that a number 
of proteins, including CD9 and CD81, were no longer 
associated with α3β1 integrin in the absence of CD151 
(Fig. 4C). Interestingly, we also detected a marked 
decrease in the association with claudin-3 (Fig. 4D), a 
tight junction protein and a driver of ovarian tumor growth 
and metastasis [30, 31]. In line with these observations 
is that knockdown of α3β1 integrin enhanced tumor cell 
proliferation (Fig. 5A). However, removal of E-cadherin, 
had little effect on the proliferation of OVCAR-5 cells, and 
was accompanied by a concomitant increase in α3 integrin 
expression (Fig. 5B). In line with a suppressive role of 
α3 integrin is a trend towards reduced mRNA expression 
of this gene in ovarian tumors (Fig. 5C), similar to the 
prior analysis of CD151 (Fig. 1E). Collectively, these 
results provide evidence that CD151 and α3β1 integrin 
act together to suppress human ovarian tumor growth 
and dissemination by regulating the integrity of cell-cell 
contacts among tumor cells.
CD151 removal enhances the activation of EMT-
inducing transcription factor Slug 
Building on our previous finding where CD151 
removal gave rise to an EMT-like morphology in ovarian 
cancer cells (Fig. 4), we evaluated the state of EMT-
inducing factors. While there was minimal change in the 
expression of Twist, Snail or ZEB protein upon CD151 
ablation (data not shown), expression of Slug proteins 
increased by 1.8-3.5-fold in OVCAR-5 and OVCAR-420 
tumor cells (Fig. 6A). Furthermore, our genome-wide 
expression profiling analyses indicated that CD151 
removal led to a minimal change in the mRNA of Slug 
(data not shown). Hence, we speculate that the increased 
Slug expression in CD151-deficient ovarian tumor cells 
may be largely attributed to post-translational regulation. 
In supported of elevated level of Slug protein was the 
change in a number of EMT-associated genes in CD151-
deficient OVCAR-5 cells, including fibronectin (FN1) and 
Mucin 5Ac (MUC5AC) [8, 32] (Table 1). Our subsequent 
analyses indicated that increased expression of Mucin 
5Ac and fibronectin also occurred at the protein level 
(Fig. 6B). Since Slug is strongly implicated in regulating 
epithelial cell proliferation [33], we next tested if CD151 
removal impacted ovarian tumor cell properties in a Slug-
dependent manner. As shown in Fig. 6C, Slug knockdown 
indeed led to a marked decrease in the proliferation of 
CD151-deficient OVCAR-5 cells. Taken together, these 
observations consistently suggest that CD151 plays a 
suppressive role in ovarian carcinoma growth largely 
by counteracting Slug-mediated EMT-like process. This 
includes alterations in cell-cell contact and a phenotypic 
switch to the mesenchymal phenotype as reflected by cell 
scattering and increased expression of fibronectin and 
Muc5Ac. 
CD151 removal in ovarian cancer cells is 
accompanied by an induction of Wnt signaling 
To understand how CD151 regulated Slug in ovarian 
cancer cells, we turned our attention to Wnt signaling, as 
it has been strongly connected to the activation of Slug 
in human carcinomas [34, 35]. In fact, our DNA array 
analyses revealed marked changes in a number of Wnt 
pathway-related genes. Notably, upon CD151 ablation, 
KIAA1199 and RNF43, two newly identified regulators of 
Wnt signaling [36-38], increased by 18- and 7-fold at the 
mRNA level, respectively (Table 1). Also, similar changes 
in the RNF43 gene occurred at the protein level (data not 
shown). Moreover, CD151-deficient ovarian cancer cells 
Figure 7: Induction of canonical Wnt signaling in 
ovarian cancer cells upon CD151 removal. A Blotting 
of key signaling intermediates in Wnt pathways in OVCAR-5 
cells expressing control and CD151-specific shRNA. Tumor 
cells were lysed in RIPA buffer and blotted with antibodies 
against Wnt signaling molecules (i.e., β-catenin and Axin-2) 
as well as total and phosphorylated forms of GSK-3β kinase. 
Tublin was blotted as control. The fold change in protein level 
was estimated according to densitometry analyses. B Impact of 
CD151 knockdown on tumor cell viability in response to the 
treatment of ICG-001, an inhibitor disrupting the transcription 
within the canonical Wnt/β-catenin/TCF/CBP signaling axis. 
OVCAR-5 cells with or without CD151 knockdown were 
seeded into 48 well plates and then treated with varying dosages 
of Wnt inhibitor for 72 hours prior to being analyzed by MTT 
assay. C Schematic illustration of functional roles of CD151-
α3β1 integrin complexes in ovarian cancer. 
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displayed a 2-8-fold increase in β-catenin and Axin-2 
proteins, two key signaling intermediates downstream 
of the canonical Wnt pathway (Fig. 7A). Our luciferase 
reporter assay with FOPFLASH reporter construct, 
however, revealed little change in the transcriptional 
activity of β-catenin/TCF complexes upon CD151 
removal, regardless of Wnt3A stimulation (data not 
shown), implying a constitutive activation of β-catenin-
mediated signaling. In line with these observations is that 
upon treatment with ICG-001, an inhibitor specifically 
disrupting the transcription mediated by β-catenin/
CBP complexes [39], CD151-deficient OVCAR-5 cells 
displayed significantly higher viability over a range of 4 to 
126 µM, compared to the control (Fig. 7B). It is also worth 
noting that there was minimal change in the activation 
in PI3K/AKT- or RAS/MAPPK-mediated pathways in 
ovarian carcinoma cells upon CD151 ablation (data not 
shown). Collectively, these data indicate a novel signaling 
cross-talk between CD151 and the canonical Wnt/β-
catenin/CBP axis-mediated pathway in ovarian cancer 
cells.
DISCUSSION
This study presents first clinical and experimental 
evidence of the suppressive role of CD151 and its 
associated α3β1 integrin in serous-type ovarian cancer. 
IHC and genomic analyses of human ovarian tumor tissues 
suggest an inverse correlation between CD151 expression 
and tumor metastasis. Consistent with this observation 
is that CD151 ablation markedly impacts ovarian tumor 
cell proliferation as well as tumor growth and ascites 
production in immuno-compromised mice. Furthermore, 
E-cadherin expression and cell-cell contacts in ovarian 
tumor cells were markedly altered upon disruption of 
CD151 and/or α3β1 integrin. In line with this EMT-like 
alteration is the concomitant activation of transcription 
factor Slug and canonical Wnt signaling. Taken together, 
our results demonstrate that CD151 and α3β1 integrin 
act together to suppress ovarian tumor cell growth and 
malignancy largely by controlling cell-cell contacts, Wnt 
signaling and Slug activation (Fig. 7C).
CD151- α3β1 integrin complexes suppress 
tumorigenesis by counteracting the EMT-like 
process
Our analyses of clinical specimens, tumor cell 
activities and xenograft models support a tumor-
suppressive role of CD151-α3β1 integrin complexes in 
ovarian cancer. This finding is consistent with the recent 
studies on CD151 in human endometrial and colon cancers 
[40, 41]. In addition, a similar suppressive role in tumor 
progression has been described for α3β1 integrin [42, 43]. 
These observations differ from the reports on the function 
of these molecules in other cancer types, including breast 
and prostate cancer [19, 44, 45]. It has been suggested that 
the complex roles of LB integrins during carcinogenesis 
are dependent on the oncogenic contexts [29, 46]. In this 
regard, the tumor-suppressive function of CD151-integrin 
complexes described in the current study may be partially 
associated with unique oncogenic activations in human 
serous ovarian cancer revealed by recent genome-wide 
analyses [4, 47].
Aside from genetic factors, the tumor-suppressive 
role of CD151-α3β1 integrin complexes in ovarian cancer 
may be related to their roles in maintaining stable cell-cell 
contact [12, 17]. Our data show that intact CD151-α3β1 
integrin complexes inhibit the induction of the EMT-like 
process (Figs. 4-6), a critical driver of ovarian cancer 
progression and metastasis [1, 9]. Interestingly, in addition 
to decreased expression of E-cadherin, CD151 removal 
leads to a marked induction in fibronectin (FN) (Figs.4- 6), 
a strong promoter of ovarian cancer malignancy [7, 8, 48]. 
Such functional shift from E-cadherin- and LB integrin-
mediated cell-cell contact to α5β1 integrin-mediated 
cell-ECM (i.e., fibronectin) interaction may also explain 
why there is elevated activation of small GTPase RhoA 
in CD151-deficient carcinoma cells recently described by 
Johnson et al [12, 29]. In support of this notion is that 
the engagement of fibronectin with its primary receptor, 
α5β1 integrin, is more effective in activating RhoA, 
compared to the interaction between laminins and their 
integrin receptors [49]. Consequently, our study raises the 
possibility that CD151-α3β1 integrin complexes impact 
ovarian cancer malignancy largely by repressing the EMT-
like process and potentially the RhoA activation from 
fibronectin-α5β1 integrin-mediated signaling.
Data from the current study also suggest that the 
induction of the EMT-like event upon the disruption 
of CD151-integrin complexes may result from the 
activation of transcription factor Slug as well as increased 
cytoplasmic and nuclear expression of β-catenin. In fact, 
as master regulators of EMT, increased transcriptional 
activities of Slug and β-catenin have been associated 
with a broad spectrum of tumorigenic processes [50, 
51]. Consistent with our observations (Figs. 3-5) is 
the promoting role of these two transcription factors in 
ovarian cancer development and malignancy described by 
multiple studies [9, 52-54]. At the present time, however, 
how CD151 removal leads to the increased expression or 
activation of Slug and β-catenin in ovarian cancer remains 
unclear. 
Functional links between CD151- α3β1 integrin 
complexes and oncogenic pathways 
One of the surprising observations from the current 
study is the inverse functional link between CD151-α3β1 
integrin complexes and the signaling of canonical Wnt 
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pathways in ovarian cancer. This finding is consistent 
with recent studies on tetraspanin molecules, such as 
tetraspanin CD9, which suppresses Wnt signaling-
dependent tumor cell proliferation and growth [55, 56]. 
In addition, these studies all point to the repression 
of β-catenin-dependent canonical Wnt signaling by 
tetraspanin molecules. Mechanistically, since minimal 
change was detected in the mRNA levels of Frizzed or 
LRP5/LRP6 in our study, the regulation of canonical Wnt 
signaling by CD151-integrin complexes may not occur at 
the receptor level. This observation is also in contrast to a 
recent report on the increase in LRP5 mRNA in CD151-
null mouse tissues [57], raising the possibility of a tissue-
specific effect of CD151 on Wnt signaling. Intriguingly, 
we also detected a marked elevation in the expression of 
KIAA1199 and RNF43 in CD151-deficient ovarian tumor 
cells (Table 1), two newly identified negative regulators 
of Wnt signaling [38, 58], implying a potential feedback 
mechanism related to CD151 function. Collectively, the 
marked changes in these important effectors and regulators 
of Wnt signaling underscore the complex signaling roles 
of CD151-α3β1 integrin complexes in ovarian tumor 
growth and progression. 
Sequestering of pro-tumorigenic regulators within 
TEMM by CD151-integrin complexes
Additional evidence supporting the suppressive 
role of CD151-α3β1 integrin complexes in ovarian cancer 
comes from the loss of tumor-promoting molecules within 
CD151-deficient TEMM, such as CD9 and claudin-3 
(Fig. 4). In fact, both CD9 and claudin-3 proteins are 
present in TEMM on tumor cells [28, 29, 59] and have 
been strongly linked to cancer malignancy [30, 31, 60]. In 
particular, CD9 has been shown to promote ovarian cancer 
cell dissemination by influencing integrin activation [31]. 
It has also been suggested that claudin-3 drives ovarian 
tumor progression and metastasis by controlling cell-cell 
contacts and Wnt signaling [61]. Conceivably, CD151 may 
regulate ovarian tumor growth and dissemination, at least 
in part, by sequestering the function of tumor-promoting 
molecules such as CD9 and claudin-3 within the TEMM 
in ovarian tumor cells.
Clinical significance of CD151-integrin complexes 
as ovarian tumor suppressors 
Results from the current study have important 
implications for the diagnosis and treatment of human 
ovarian cancer. In particular, we found that two secreted 
proteins, Mucin 5Ac and fibronectin, exhibit elevated 
expression upon the disruption of CD151-α3β1 integrin 
complexes (Table 1 & Fig. 6). In addition, like CA125, 
a common biomarker for ovarian cancer [62, 63], 
Mucin 5Ac belongs to the Mucin family, and has been 
implicated in promoting ovarian cancer progression [32]. 
Hence, evaluating these CD151-α3β1 integrin complex-
associated effectors as new biomarkers may aid in the 
future detection or diagnosis of human ovarian cancer 
malignancy. Moreover, the pro-malignancy factors or 
pathways counteracted by CD151 and α3β1 integrin 
may serve as therapeutic targets against ovarian cancer. 
Based on our observations (Figs. 6-7), the inhibitors of 
the transcriptional factor Slug or β-catenin-dependent 
canonical Wnt signaling pathway (Figs. 6-7) are 
potentially effective in disrupting the malignancy of 
ovarian cancer. 
In summary, our study demonstrates a suppressive 
role of CD151 and associated α3β1 integrin in ovarian 
tumor cell proliferation, growth and ascites production. 
Mechanistically, CD151 conveys its tumor-suppressing 
function largely by stabilizing α3β1 integrin- and 
E-cadherin-mediated cell-cell contact, while counteracting 
the EMT-like process through repressing the activation of 
Slug and canonical Wnt signaling. As such, our study has 
identified a new set of molecular pathways and regulators 
as candidate biomarkers and therapeutic targets for the 
treatment of aggressive serous-type ovarian cancer.
METHODS
Human ovarian TMA, cell lines and culture 
TMA harboring paraffin-embedded human ovarian 
tumors prepared from a broad spectrum of ovarian cancer 
patients (Supplementary Table S1) were obtained from 
Biomax (NY). The in-house TMA containing matched 
primary tumors and metastatic lesions from individual 
patients were described in a prior study [64]. Human 
ovarian cancer cell lines, including CAOV3, OVCAR-5, 
OVCAR-8, OVCAR-420, OVCAR-429, OVCAR-433, 
IgRov and SK-OV-3, were purchased from ATCC 
(Manassas, VA). All cell lines were cultured in RPMI 1640 
supplemented in 10% FBS under 5% CO2. 
Antibodies and reagents
Anti-integrin α2 (ΙΙΕ10), α3 (X8), α6 (ELE) 
and β1 (P5D2), along with anti-tetraspanin CD151 
(5C11), CD9 (C9BB) and CD82 (M104), were raised 
in-house as described in prior studies [19]. The CD151-
specific monoclonal antibody used for IHC analyses 
was obtained from Leica Microsystems, Inc. (Buffalo 
Grove, IL). Antibodies against fibronectin and Mucin 
5Ac were purchased from Sigma-Aldrich (St. Louis, 
MO). Antibodies recognizing total and phospho-Akt 
or MAPK or GSK3-β, along with those against Snail, 
Slug, LRP5, LPR6 and Axin-2, were obtained from Cell 
Signaling Technology (Danvers, MA). Antibodies against 
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E-cadherin, Twist, Zeb1 and Zeb2 were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Matrigel 
invasion chambers and anti-β4 integrin antibody were 
purchased from BD Biosciences (Franklin Lake, NJ). 
ICG-001, an inhibitor of canonical Wnt signaling, was 
obtained from Selleckchem (Houston, TX).
Assays for cell proliferation, apoptosis, adhesion, 
motility and invasion 
Changes in ovarian tumor cell proliferation or 
viability when subjected to Wnt inhibitor treatment 
were determined by MTT assay. Change in cell cycle 
and apoptosis was measured by staining fixed cells with 
propidium iodide, followed by analyses on flow cytometry. 
The assays for cell adhesion and invasion were carried out 
as previously described [19]. For measurement of random 
cell motility, cells were seeded into 24 well plates at 1.5 
x104 per well and placed inside OKALAB incubator 
with a heater and gas mixer constant at 37 0C and 5% 
CO2. The cells were imaged at 20 min intervals for the 
indicated length of time with a Nikon Automated Eclipse 
Ti-E inverted microscope. Quantitation of individual cell 
movement indicated by distance, was measured by using 
Nikon NIS-Elements Advanced Analysis Software as 
previously described [18] . 
RNAi, transfection, FACS , immunofluorescence 
analysis (IF) and IHC analyses
Stable knockdown of CD151 and Slug was carried 
out as previously described . The siRNA for α3 integrin 
was obtained from Thermo Scientific (Pittsburgh, PA) as 
described in our prior study and siRNA for E-Cadherin 
was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA). The shRNA for Slug was purchased from 
Addgene (Cambridge, MA). The surface expression 
of integrins and tetraspanins was determined by FACS 
analyses of 10,000 cells on flow cytometry at UK core 
facility. For indirect immunofluorescence analyses of cell 
surface proteins, cells were incubated with primary and 
fluorescence-conjugated antibodies on ice before being 
fixed in 2% paraformaldehyde, and visualized under a 
confocal microscope. 
IHC analyses of TMAs and human fallopian tube 
tissues were conducted essentially as described in our 
prior study [18, 19]. In brief, the antigen was retrieved 
by use of the decloaking chamber in the presence of 
0.01 mol/L EDTA buffer (pH 9.0). After blocking in 
goat serum, TMA slides were incubated with CD151-
specific monoclonal antibody, followed by incubation 
with biotinylated secondary antibody, and finally 
developed using DAB Kit (BD Bioscience, San Jose, 
CA) and counterstained with hematoxylin. The scoring of 
immunostaining was evaluated on the bases of staining 
intensity and percentages of positively stained areas by 
three independent staff members as previously described 
[19]. 
Signaling, [3H]-palmitate labeling, co-
immunoprecipitation and western blot analyses 
For evaluation of the effect of CD151 on cell 
signaling, semi-confluent ovarian cancer cells grown 
under various conditions were lysed in RIPA buffer 
supplemented with protease and phosphatase inhibitors, 
and subsequently blotted with indicated antibodies. The 
compositions of RIPA buffer were described elsewhere 
[26]. For co-immunoprecipitation of tetraspanin-integrin 
complexes, cultured human ovarian cancer cells were 
radio-labeled with 0.2 µCi [3H]-palmitate for 3 hours prior 
to being lysed in 1% Brij-96 buffer as previously described 
[65]. The biotin-labeling of cell surface molecules were 
carried out as previously described [65]. The cell lysates 
were then immunoprecipitated with indicated tetraspanin 
or integrin-specific antibodies. The immune complexes or 
cell lysates were separated on SDS-PAGE, transferred onto 
a nitrocellulose membrane and exposed to radiography or 
blotted with indicated antibodies.
Xenograft analyses 
Analyses of ovarian tumor growth were conducted 
by subcutaneously injecting control and CD151-ablated 
OVCAR-5 cells into the flanks of immune-compromised 
nude mice (Charles River, MA) at 1x 106 cells per site. 
For analyses of ascites production, 1x 106 (in 200 µl) 
OVCAR-5 cells were injected into the peritoneal body 
cavity of nude mice at 5 animals per group. During the 
animal studies, mice were monitored daily for the initial 
appearance of palpable tumors or an enlarged abdomen 
due to ascites production. The tumor sizes were measured 
twice a week with calipers and volumes were calculated 
using the formula of length x width x height x 0.52. All 
animals were terminated with the apparent appearance 
of disease. At the end of the experiments, tumors derived 
from subcutaneously injected mice were collected and 
fixed in 10% neutral formalin (Sigma-Aldrich, St. Louis, 
MO) and stored in 70% ethanol prior to being embedded 
into paraffin blocs for H & E staining.
Gene expression profiling analyses 
To conduct DNA array analyses, total RNA was 
extracted from semi-confluent human OVCAR-5 cells 
expressing control and CD151-specific shRNA by use of 
the Trizol method (Life Technologies, Grand Island, NY) 




All experiments described in the study were 
independently repeated. The Fisher exact test was 
performed on the association of CD151 expression in 
metastatic lesions of human ovarian tumors in TMA. The 
paired student t-test was conducted to assess the difference 
in CD151 staining between 7 paired human primary 
ovarian tumors and metastatic lesions or the impact of 
CD151 knockdown on ovarian tumor growth. Difference 
in tumor-free survival was assessed by the log-rank test. 
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